Loading stock data…
Agenus Inc. (AGEN)
$7.52-0.72 (-8.74%)
Market OpenUpdated 3:44 PM EDT
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agenus Inc. in the Healthcare sector is trading at $7.52 with a market capitalization of $371M. Wall Street consensus targets $19.50 (2 analysts), implying a +159.3% move over the next 12 months. The stock is currently 15% below its 52-week high of $8.85, remaining 77.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +159.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $34.52M↑ | $33.74M↓ | $34.20M↑ | $30.23M↑ | $25.69M |
| Gross Profit | $19.76M↓ | $21.91M↓ | $26.69M↑ | $6.00M↑ | -$1.26M |
| Operating Income | $11.29M↓ | $15.05M↑ | $14.40M↑ | -$4.86M↑ | -$16.78M |
| Net Income | -$550,000↓ | $39.23M↑ | -$10.58M↓ | $63.91M↑ | -$27.95M |
Peer Comparison
JNJUNHPFE
Fundamentals
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identificati...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$370.88M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
2.76
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-46.22%
Volume
Today's trading volume
955,365
Recent News
Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions
The latest analyst update on Agenus centers on a reset of its fair value estimate, with the price target moving from US$30.00 to US$19.50. This change reflects recent Street research that balances optimism about the refocused botensilimab and balstilimab pipeline with caution around financing plans and execution risks. As you read on, you will see how these shifting targets fit into the broader Agenus story and what to watch to keep up with the evolving narrative. Stay updated as the Fair...
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Earnings Expected to Grow: Should You Buy?
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Agenus Stock We Don't?
Investors need to pay close attention to AGEN stock based on the movements in the options market lately.